Canbiola Reports Second Quarter 2019 Results
Revenue Increased by 311%
Closed $3.9 Million Equity Raise Completed
Hicksville NY - 
(NewMediaWire) - August 20, 2019 - Canbiola, Inc. (OTCQB: CANB) (“Canbiola” or the “Company”), a developer, manufacturer and seller of a variety of hemp-derived THC-Free Cannabidiol (CBD) Isolate products such as oils, drops/tinctures, creams, moisturizers, chews, and capsules, announced today the company's financial results for the second quarter ended June 30, 2019.
Key Financial Highlights for Q2 2019:
- Revenues increased by 311% to $633,579
- Gross margin of 52.8%
- Operating loss of $1,435,289, included $959,948 in non-cash stock-based compensation
- Closed $3,936,700 cash raised subsequent to the end of the quarter
Key Business Highlights for Q2 2019:
- Appointed David Woycik, Jr. to Corporate Advisory Board
- Completed a 300% increased investment in its Duramed division to combat the opioid crisis
- Conducted its Annual Shareholder Meeting on June 14
- Created a joint venture with NY SHI and Shi Farms to become vertically integrated
Management Commentary
“Our second-quarter results reflect the continued business traction and growth we are achieving from the wide variety of our CBD products. Our focus on the medical community has been key in driving our growth, as our products are now in over 300 medical offices and health professionals,” commented, Canbiola Chief Executive Officer Marco Alfonsi. “During the second quarter and with the subsequent closing in July, we have become vertically integrated with our joint venture with NY SHI and Shi Farms. This is a major inflection point for our Company as we seek to become a major player in the New York hemp market. This joint venture enables us to partner with local farmers to assist them in growing their business and providing us with access and rights to acquire certain isolate which will be beneficial in costs and differentiate our value.”
Recently Announced Joint Venture:
NY SHI and Shi Farms – June 12 (Letter of Intent) and July 22 (Closing)
Canbiola and its wholly-owned subsidiary, NY Hemp Depot LLC, has officially formed a joint venture with NY – SHI, LLC (“NY – SHI”) and EWSD I LLC dba Shi Farms (“Shi Farms”), a vertically-integrated high - CBD hemp cultivation company, to aggregate and purchase fully-grown, harvested industrial hemp from third-party farmers in the State of New York.
The joint venture will operate the NY Hemp Depot Facility for hemp processing in the State of New York. Additionally, it may also sell feminized seeds, clones, and additional materials required to grow industrial hemp and maximize CBD potency. NY – SHI’s cultivating license will be amended to add the NY Hemp Depot Facility. The NY Hemp Depot Facility will empower and enable local farmers, both indoor and outdoor, with technologies, products, and services to help them grow their businesses and revenues. The joint venture plans to aggregate and purchase fully-grown, harvested industrial hemp from farmers in New York, who are growing such industrial hemp on their own properties and, in the future, to solicit farmers to grow industrial hemp on behalf of the joint venture under NY – SHI’s cultivating license.
NY Hemp Depot LLC, a wholly-owned subsidiary of Canbiola, has full and complete discretion to manage and control the joint venture. NY Hemp Depot LLC is providing a building for the operation of the NY Hemp Depot Facility, location services, management, and day-to-day operations, and services for the recruitment of farmers.
Shi Farms, which is a dba for EWSD I, LLC, is a licensed Hemp Cultivation Operation under the Colorado Department of Agriculture, operating a 300-acre farm and 40,000 square feet of research greenhouses. NY – SHI is providing to the joint venture technical expertise regarding the growth and cultivation of industrial hemp, growing technology and expertise, use of its cultivating license that will be amended to add the NY Hemp Depot Facility, and services for the recruitment of farmers. NY – SHI agreed to sell certain products to the joint venture, including feminized hemp seeds and/or clone plants, at the prevailing market price for such products at the time of the sale, for the joint venture to sell to farmers.
Canbiola also has the right to acquire certain isolate from Shi Farms at the cost of processing the isolate from biomass. The biomass would be aggregated and then shipped to Shi Farms’ facility in Pueblo, Colorado, where it would be processed by Shi Farms’ other joint-venture partner, Mile High Labs, Inc. The amalgamation and processing will be done by Mile High Labs’ The Monster (https://www.milehighlabs.com). Shi Farms granted Canbiola’s wholly-owned subsidiary, NY Hemp Depot, LLC, a minority interest in the one and one-half percent payments due to Shi Farms in connection with its agreements with Mile High Labs, Inc.
Financial Results for the Three Months Ended June 30, 2019:
Revenue for the three months ended June 30, 2019, was $633,579, an increase of $479,388 or 311%, compared to $154,191 for the three months ended June 30, 2018.
Gross profit for the three months ended June 30, 2019, was $334,375, an increase of $227,036 or 212%, compared to $107,339 for the three months ended June 30, 2018. The resulting gross margin was 52.8% for the three months ended June 30, 2019, compared to 69.6% for the three months ended June 30, 2018.
Operating expenses for the three months ended June 30, 2019, were $1,769,664, an increase of $1,193,890 or 207%, compared to $575,774 for the three months ended June 30, 2018. For the three months ended June 30, 2019, operating expenses included non-cash stock-based compensation of $959,948 paid to officers, employees, and service of consultants, compared to $344,869 for the three months ended June 30, 2018.
Operating loss for the three months ended June 30, 2019, was $1,435,289, an increase of $966,854, or 206%, compared to $468,435 for the three months ended June 30, 2018.
Adjusted operating loss for the three months ended June 30, 2019, was $475,341, an increase of $351,775, or 285%, compared to $123,566 for the three months ended June 30, 2018. Adjusted operating loss does not include non-cash stock-based compensation.
Net loss for the three months ended June 30, 2019, was $1,437,491, an increase of $462,615, or 47%, compared to $974,876 for the three months ended June 30, 2018. The resulting EPS loss for the three months ended June 30, 2019, was ($0.00) per diluted share, compared to ($0.00) per diluted share for the three months ended June 30, 2018.
Financial Results for the Six Months Ended June 30, 2019:
Revenue for the six months ended June 30, 2019 was $1,150,739, an increase of $926,779 or 414%, compared to $223,960 for the six months ended June 30, 2018.
Gross profit for the six months ended June 30, 2019, was $588,982, an increase of $456,461 or 344%, compared to $132,521 for the six months ended June 30, 2018. The resulting gross margin was 51.2% for the six months ended June 30, 2019, compared to 59.2% for the six months ended June 30, 2018.
Operating expenses for the six months ended June 30, 2019, were $3,196,339, an increase of $1,960,692 or 159%, compared to $1,235,647 for the six months ended June 30, 2018. For the six months ended June 30, 2019, operating expenses included non-cash stock-based compensation of $1,788,144 paid to officers, employees, and service of consultants, compared to $758,177 for the six months ended June 30, 2018.
Operating loss for the six months ended June 30, 2019 was $2,607,357, an increase of $1,504,231, or 136%, compared to $1,103,126 for the six months ended June 30, 2018.
Adjusted operating loss for the six months ended June 30, 2019, was $819,203, an increase of $474,254, or 137%, compared to $344,949 for the six months ended June 30, 2018. Adjusted operating loss does not include non-cash stock-based compensation.
Net loss for the six months ended June 30, 2019 was $2,610,005, an increase of $2,042,687, or 360%, compared to $567,318 for the six months ended June 30, 2018. The resulting EPS loss for the six months ended June 30, 2019, was ($0.00) per diluted share, compared to ($0.00) per diluted share for the six months ended June 30, 2018.
About Canbiola, Inc.
Canbiola, Inc. (OTCQB: CANB) is a vertically integrated conglomerate specializing in the manufacturing, formulation, and sale of THC-Free Cannabidiol (CBD) Isolate products such as oils, drops/tinctures, gels, creams, moisturizers, chews, and capsules. All Canbiola products are organic and Non-GMO, free of impurities and contaminants, and formulated with the finest ingredients to the highest manufacturing standards. All products are certified for purity and accuracy by third-party laboratory verification.
Canbiola pursues an aggressive growth strategy through the continual development of proprietary products and the expansion of its offerings via strategic acquisitions in the healthcare and CBD industries.
Canbiola has created several innovative CBD product lines, marketed through targeted channels including:
The Canbiola clinical line, which is marketed and promoted through healthcare practitioners in the medical setting.
The Pure Leaf Oil (consumer brand) and Seven Chakras (spa brand) lines are sold through both online and brick & mortar retail outlets.
Canbiola’s state-of-the-art manufacturing facility in Lacey, WA is operated by Pure Health Products LLC (PHP), a wholly-owned subsidiary that produces all of the Company’s CBD Isolate products, in addition to providing private label and white label solutions for companies looking to add high-quality CBD items to their offerings. Canbiola is passionate about improving people’s lives and we take pride in providing pure CBD products infused with organic and natural ingredients. We want customers to know that they are buying lab-tested, high-quality natural products at a great price.
Canbiola’s Radical Tactical LLC subsidiary produces CBD products in other forms including vapes and gums.
Duramed Inc. and DuramedNJ LLC, wholly-owned subsidiaries of Canbiola, further the mission of providing innovative products designed to improve people’s lives, aiming to reduce their use of opioid substances through the utilization of durable medical devices. This product line includes an FDA-approved wearable low-intensity ultrasound SAM (Sustained Acoustic Medicine) device delivering multi-hour treatment intended to accelerate healing, improve function for musculoskeletal injuries (muscle, tendon, ligament) and reduce chronic pain (without opioid pain medication).
With the creation of its newest wholly-owned subsidiary, NY Hemp Depot LLC, Canbiola has attained complete vertical integration, allowing it to fully control the supply chain from seed to sale, develop customized products and maximize profit margins. Through the utilization of its newly acquired NY State Hemp Cultivation License, the Company contracts with farmers throughout the state of NY to cultivate specific strains of hemp, which is then processed into CBD Isolate products to Canbiola’s exacting manufacturing standards and specifications at the Company’s laboratory and production facility.
For more information about Canbiola, Inc., please visit: Canbiola.com
Use of Non-GAAP Financial Measures
To supplement Canbiola’s financial statements presented on a GAAP basis, Canbiola provides Adjusted Operating/EBITDA as supplemental measures of its performance.
To provide investors with additional insight and allow for a more comprehensive understanding of the information used by management in its financial and decision-making surrounding pro forma operations, we supplement our consolidated financial statements presented on a basis consistent with U.S. generally accepted accounting principles, or GAAP, with EBITDA, Adjusted EBITDA and Adjusted EPS as non-GAAP financial measures of earnings. EBITDA represents net income before income tax expense (benefit), interest expense, depreciation, and amortization. Adjusted EBITDA represents EBITDA plus stock-based compensation and change in fair value of derivative liabilities. Adjusted EPS represents Adjusted EBITDA divided by the number of fully diluted shares outstanding. Our management uses EBITDA, Adjusted EBITDA, and Adjusted EPS as financial measures to evaluate the profitability and efficiency of our business model. We use these non-GAAP financial measures to access the strength of the underlying operations of our business. These adjustments and the non-GAAP financial measures that are derived from them provide supplemental information to analyze our operations between periods and overtime. We find this especially useful when reviewing pro forma results of operations, which include large non-cash amortizations of intangible assets from acquisitions and stock-based compensation. Investors should consider our non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.
Forward-Looking Statements
Forward-looking statements and risks and uncertainties discussed in this letter contain forward-looking statements. The words "anticipate," "believe," "estimate," "may," "intend," "expect," and similar expressions identify such forward-looking statements. Expected, actual results, performance, or achievements could differ materially from those contemplated, expressed, or implied by the forward-looking statements contained herein. Forward-looking statements are subject to a number of risks and uncertainties, including but not limited to, risks and uncertainties associated with, among other things, the impact of economic, competitive, and other factors affecting our operations, markets, products, and performance. The matters discussed herein should not be construed in any way, shape or manner of our future financial condition or stock price.
Follow Canbiola on:
Twitter @CanbiolaHealth
Instagram @canbiola.inc or @canbiola_cbd or @canbiola_medical_cbd
Follow us on Twitter and Facebook
Investors and Media:
IR@canbiola.com
(516) 595-9544
Canbiola, Inc., and Subsidiary
Consolidated Balance Sheets
| June 30, 2019 | December 31, 2018 | |||||||
| (Unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 413,098 | $ | 807,747 | ||||
| Accounts receivable, less allowance for doubtful accounts of $0 and $0, respectively | 588,560 | 39,172 | ||||||
| Inventory | 87,854 | 87,104 | ||||||
| Prepaid expenses – current | 310,747 | 210,351 | ||||||
| Other receivable – current | 5,000 | - | ||||||
| Total current assets | 1,405,259 | 1,144,374 | ||||||
| Property and equipment, at cost less accumulated depreciation of $48,512 and $20,248, respectively | 991,811 | 59,619 | ||||||
| Other assets: | ||||||||
| Deposit – noncurrent | 19,786 | 48,726 | ||||||
| Prepaid expenses – noncurrent | 2,688,565 | 2,365,719 | ||||||
| Note receivable – noncurrent | 19,390 | 19,389 | ||||||
| Other receivable – noncurrent | 15,225 | - | ||||||
| Intangible assets, net of accumulated amortization of $7,160 and $0, respectively | 191,495 | - | ||||||
| Goodwill | 55,849 | 55,849 | ||||||
| Right-of-Use Asset, net of accumulated depreciation of $8,767 and $0, respectively | 81,824 | - | ||||||
| Total other assets | 3,072,134 | 2,489,683 | ||||||
| Total assets | $ | 5,469,204 | $ | 3,693,675 | ||||
| Liabilities and Stockholders’ Deficiency | ||||||||
| Current liabilities: | ||||||||
| Notes and loans payable | $ | 15,841 | $ | 19,205 | ||||
| Accounts payable | 91,135 | 73,059 | ||||||
| Accrued officers’ compensation | 68,750 | 68,750 | ||||||
| Other accrued expenses payable | 33,177 | 43,778 | ||||||
| Current portion of lease liability | 32,552 | - | ||||||
| Total current liabilities | 241,455 | 204,792 | ||||||
| Non-current portion of lease liability | 50,582 | - | ||||||
| Total liabilities | 292,037 | 204,792 | ||||||
| Commitments and contingencies (Notes 14) | ||||||||
| Stockholders’ equity: | ||||||||
| Preferred stock, authorized 5,000,000 shares: | ||||||||
| Series A Preferred stock, no par value: authorized 20 shares, issued and outstanding 20 and 18 shares, respectively | 5,539,174 | 4,557,424 | ||||||
| Series B Preferred stock, $0.001 par value: authorized 500,000 shares, issued and outstanding 342,853 and 499,958 shares, respectively | 322 | 479 | ||||||
| Common stock, no par value; authorized 1,500,000,000 shares, issued and outstanding 595,171,059 and 440,566,325 shares, respectively | 19,941,253 | 16,624,557 | ||||||
| Additional Paid-in capital | 872,976 | 872,976 | ||||||
| Additional Paid-in capital – Stock Options (Note 11) | 202,200 | 202,200 | ||||||
| Accumulated deficit | (21,378,758 | ) | (18,768,753 | ) | ||||
| Total stockholders’ equity | 5,177,167 | 3,488,883 | ||||||
| Total liabilities and stockholders’ equity | $ | 5,469,204 | $ | 3,693,675 | ||||
Canbiola, Inc. and Subsidiary
Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
| Six Months Ended June 30, | Three Months Ended June 30, | |||||||||||||||
| 2019 | 2018 | 2019 | 2018 | |||||||||||||
| Revenues | ||||||||||||||||
| Product Sales | $ | 1,147,139 | $ | 211,203 | $ | 631,779 | $ | 148,234 | ||||||||
| Service Revenue | 3,600 | 12,757 | 1,800 | 5,957 | ||||||||||||
| Total Revenues | 1,150,739 | 223,960 | 633,579 | 154,191 | ||||||||||||
| Cost of product sales | 561,757 | 91,439 | 299,204 | 46,852 | ||||||||||||
| Gross Profit | 588,982 | 132,521 | 334,375 | 107,339 | ||||||||||||
| Operating costs and expenses: | ||||||||||||||||
| Officers and director’s compensation (including stock- based compensation of $834,230, $185,400, $336,882, and $0, respectively) | 1,274,688 | 321,650 | 829,138 | 58,850 | ||||||||||||
| Consulting fees (including stock-based compensation of $953,914, $572,777, $388,138 and $344,869 respectively) | 1,091,086 | 643,676 | 427,335 | 367,769 | ||||||||||||
| Advertising expense | 153,762 | 37,008 | 127,374 | 14,675 | ||||||||||||
| Hosting expense | 7,917 | 7,478 | 7,467 | 3,810 | ||||||||||||
| Rent expense | 12,344 | 33,065 | 484 | 16,800 | ||||||||||||
| Professional fees | 112,016 | 70,339 | 74,180 | 56,956 | ||||||||||||
| Depreciation of property and equipment | 14,297 | 1,604 | 11,532 | 801 | ||||||||||||
| Amortization of intangible assets | 7,160 | - | 4,966 | - | ||||||||||||
| Other | 523,069 | 120,827 | 287,188 | 56,113 | ||||||||||||
| Total operating expenses | 3,196,339 | 1,235,647 | 1,769,664 | 575,774 | ||||||||||||
| Loss from operations | (2,607,357 | ) | (1,103,126 | ) | (1,435,289 | ) | (468,435 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest income | 317 | 5,024 | 317 | 2,512 | ||||||||||||
| Income from derivative liability | - | 844,051 | - | (231,655 | ) | |||||||||||
| Loss on stock issuance | (185,104 | ) | (185,104 | ) | ||||||||||||
| Loss on debt conversion | (57,738 | ) | (57,738 | ) | ||||||||||||
| Interest expense (including amortization of debt discounts of $0 and $54,165, respectively) | (2,965 | ) | (70,425 | ) | (2,519 | ) | (34,456 | ) | ||||||||
| Other income (expense) - net | (2,648 | ) | 535,808 | (2,202 | ) | (506,441 | ) | |||||||||
| Loss before provision for income taxes | (2,610,005 | ) | (567,318 | ) | (1,437,491 | ) | (974,876 | ) | ||||||||
| Provision for income taxes | - | - | - | - | ||||||||||||
| Loss and comprehensive loss | $ | (2,610,005 | ) | $ | (567,318 | ) | (1,437,491 | ) | (974,876 | ) | ||||||
| Net income (loss) per common share - basic and diluted | $ | 0.00 | $ | 0.00 | 0.00 | 0.00 | ||||||||||
| Weighted average common shares outstanding – | ||||||||||||||||
| Basic | 532,985,996 | 232,957,482 | 564,041,249 | 236,270,276 | ||||||||||||
| Diluted | 781,082,928 | 371,751,524 | 715,286,813 | 377,833,277 | ||||||||||||
Canbiola, Inc. and Subsidiary
Consolidated Statements of Cash Flows
(Unaudited)
| Six Months Ended June 30, | ||||||||
| 2019 | 2018 | |||||||
| Operating Activities: | ||||||||
| Net loss | $ | (2,610,005 | ) | $ | (567,318 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Stock based compensation, net of prepaid stock- based consulting fees |
1,553,216 | 758,177 | ||||||
| Loss on stock issuance | - | 185,104 | ||||||
| Loss on debt conversion | - | 57,738 | ||||||
| Debt issuance expense | - | 14,000 | ||||||
| Expense from derivative liability | - | (844,051 | ) | |||||
| Depreciation of property and equipment - General | 14,296 | 1,604 | ||||||
| Depreciation of property and equipment - COGS | 24,973 | - | ||||||
| Amortization of intangible assets | 7,160 | - | ||||||
| Amortization of debt discounts | - | 54,165 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | (549,388 | ) | (8,057 | ) | ||||
| Inventory | (750 | ) | 2,712 | |||||
| Prepaid expenses | (7,850 | ) | - | |||||
| Other receivable | (20,225 | ) | - | |||||
| Security deposit | 28,940 | - | ||||||
| Accounts payable | 18,076 | (10,906 | ) | |||||
| Accrued officers’ compensation | - | 72,500 | ||||||
| Other accrued expenses payable | (10,601 | ) | 10,607 | |||||
| Net cash used in operating activities | (1,317,230 | ) | (273,725 | ) | ||||
| Investing Activities: | ||||||||
| Intangible assets additions | (50,000 | ) | - | |||||
| Fixed assets additions | (962,698 | ) | (38,355 | ) | ||||
| Net cash used in investing activities | (1,012,698 | ) | (38,355 | ) | ||||
| Financing Activities: | ||||||||
| Repayments of notes and loans payable | (3,364 | ) | - | |||||
| Repayments of lease liability | (7,457 | ) | - | |||||
| Proceeds received from notes and loans payable | - | 135,000 | ||||||
| Proceeds from sale of common stock | 1,946,100 | - | ||||||
| Proceeds from sale of Series B preferred stock | - | 249,000 | ||||||
| Net cash provided by financing activities | 1,935,279 | 384,000 | ||||||
| Increase (decrease) in cash and cash equivalents | (394,649 | ) | 71,920 | |||||
| Cash and cash equivalents, beginning of period | 807,747 | 1,652 | ||||||
| Cash and cash equivalents, end of period | $ | 413,098 | $ | 73,572 | ||||
| SUPPLEMENTAL CASH FLOW INFORMATION: | ||||||||
| Income taxes paid | $ | - | $ | - | ||||
| Interest paid | $ | - | $ | - | ||||
| NON-CASH INVESTING AND FINANCING ACTIVITIES: | ||||||||
| Issuance of common stock in acquisition of Intangible assets | $ | 148,655 | $ | - | ||||
| Issuance of common stock in satisfaction of Officers compensation | $ | 54,340 | $ | - | ||||
| Issuance of common stock in satisfaction of debt | $ | - | $ | 15,000 | ||||
| Issuance of common stock in satisfaction of directors’ fees | $ | - | $ | 202,800 | ||||
| Issuance of common stock in satisfaction of Accrued interest | $ | - | 4,246 | |||||
| Issuance of common stock for services rendered | $ | 497,220 | $ | - | ||||
Company News
